Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

Mosliciguat

Status:

Phase 2

Condition:

Pulmonary Hypertension

Intervention Type:

Inhaled Drug

Funder Type:

Industry

Drug Details

Mosliciguat is a soluble guanylate cyclase (sGC) activator. It has the potential to be first-in-class and to have a differentiated mechanism of action (MOA). Mosliciguat’s MOA is thought to drive vasodilation, including in conditions characterized by increased lung tissue hypoxia and oxidative stress, and may have anti-inflammatory and anti-fibrotic properties.

Study Purpose

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Find a Clinical Trial